Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The entity "novel transcript, antisense to SLC25A26" (ENSG00000307959) refers to a predicted or uncharacterized transcript located antisense to the solute carrier family 25 member 26 (SLC25A26) gene region. There is currently no curated information or characterization indicating that this transcript is a recognized therapeutic target, enzyme, transporter, receptor, or protein-coding gene. The canonical human gene in this region, SLC25A26, encodes the mitochondrial S-adenosylmethionine carrier, which is involved in mitochondrial methylation processes and is implicated in cancer and mitochondrial disease[1][2][3]. In contrast, the antisense "novel transcript" is neither established as a molecular target nor well documented. Its nomenclature and lack of functional assignment suggest potential issues with annotation, incomplete information, or that it is simply a computational prediction without biological validation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript antisense to solute carrier family 25 member 26 (ENSG00000307959).